NCT06176339 is a Phase 2 clinical trial of Pentoxifylline Oral Tablet in Breast Cancer Female, sponsored by Mansoura University.

Who is sponsoring NCT06176339?

NCT06176339 is sponsored by Mansoura University.

What drugs are being tested in NCT06176339?

Interventions in NCT06176339: Pentoxifylline Oral Tablet, Placebo.

What condition does NCT06176339 study?

NCT06176339 studies Breast Cancer Female.

Is NCT06176339 still recruiting?

NCT06176339 is currently status unknown. Last updated 15 March 2024.

Last reviewed 2024-03-15 · How we verify

NCT06176339

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients"

Status unknown Phase 2 Last updated 15 March 2024

What this trial tests

Phase 2 trial testing Pentoxifylline Oral Tablet in Breast Cancer Female in 70 participants. Status unknown.

Timeline

15 December 2023

Primary endpoint
30 August 2024

30 September 2024

Quick facts

Lead sponsor	Mansoura University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	70
Start date	15 December 2023
Primary completion	30 August 2024
Estimated completion	30 September 2024
Sites	1 location across Egypt

Drugs / interventions tested

Pentoxifylline Oral Tablet — full drug profile →
Placebo

Conditions studied

Breast Cancer Female — all drugs for Breast Cancer Female →

Sponsor

Mansoura University

Who can join

Adults 18 to 65, any sex, with Breast Cancer Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Breast cancer, a leading cause of cancer-related mortality in women worldwide, has spurred the investigation of novel therapeutic approaches. Pentoxifylline (PTX), a synthetic methylxanthine derivative, has shown promise in preclinical studies when combined with conventional anticancer drugs. This study aims to assess PTX's impact when added to neoadjuvant chemotherapy protocols in breast cancer patients, with the goal of improving treatment outcomes and reducing associated toxicities.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Oxidative Stress and Age-Related Tumors.
Di Carlo E, Sorrentino C. · · 2024 · cited 33× · PMID 39334768 · DOI 10.3390/antiox13091109

Verify or expand the search:

Other trials of Pentoxifylline Oral Tablet

Trials testing the same drug.

NCT06265389 — Pentoxifylline as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia; A New Perspective of an Old Drug · Phase 4 · completed
NCT03060434 — Pentoxifylline and Lumbar Radiculopathy · Phase 4 · active not recruiting

Other recruiting trials for Breast Cancer Female

Currently open trials in the same condition.

NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
NCT07214883 — UCF MammoChat: Image Repository · recruiting
NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting

Other Mansoura University trials

Trials by the same sponsor.

NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
NCT07534943 — Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Period · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06176339 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mansoura University
Last refreshed: 15 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06176339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing